Literature DB >> 31047905

Clinical and Patient-reported Outcome Measures in Men Referred for Consideration of Surgery to Treat Lower Urinary Tract Symptoms: Baseline Results and Diagnostic Findings of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM).

Amanda L Lewis1, Grace J Young1, Paul Abrams2, Peter S Blair1, Christopher Chapple3, Cathryn M A Glazener4, Jeremy Horwood1, John S McGrath5, Sian Noble6, Gordon T Taylor7, Hiroki Ito2, Mohammed Belal8, Melissa C Davies9, Andrew J Dickinson10, Charlotte L Foley11, Steve Foley12, Simon Fulford13, Mohsen M Gammal14, Mary Garthwaite13, Mark R E Harris15, Petre C Ilie16, Robert Jones17, Samer Sabbagh18, Robert G Mason19, Ester McLarty10, Vibhash Mishra20, Jaswant Mom21, Roland Morley22, Salvatore Natale10, Tharani Nitkunan23, Tobias Page24, David Payne25, Tina G Rashid22, Kasra Saeb-Parsy26, Sarb S Sandhu27, Adrian Simoes28, Gurpreet Singh14, Mark Sullivan29, Heidi V Tempest29, Srinivasa Viswanath30, Roger M H Walker23, J Athene Lane1, Marcus J Drake31.   

Abstract

BACKGROUND: Clinical evaluation of male lower urinary tract symptoms (MLUTS) in secondary care uses a range of assessments. It is unknown how MLUTS evaluation influences outcome of therapy recommendations and choice, notably urodynamics (UDS; filling cystometry and pressure flow studies).
OBJECTIVE: To report participants' sociodemographic and clinical characteristics, and initial diagnostic findings of the Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM). UPSTREAM is a randomised controlled trial evaluating whether symptoms are noninferior and surgery rates are lower if UDS is included. DESIGN, SETTING, AND PARTICIPANTS: A total of 820 men (≥18 yr of age) seeking treatment for bothersome LUTS were recruited from 26 National Health Service hospital urology departments. INTERVENTION: Care pathway based on routine, noninvasive tests (control) or routine care plus UDS (intervention arm). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome is International Prostate Symptom Score (IPSS) and the key secondary outcome is surgery rates 18 mo after randomisation. International Consultation on Incontinence Questionnaires were captured for MLUTS, sexual function, and UDS satisfaction. Baseline clinical and patient-reported outcome measures (PROMs), and UDS findings were informally compared between arms. Trends across age groups for urinary and sexual PROMs were evaluated with a Cuzick's test, and questionnaire items were compared using Pearson's correlation coefficient. RESULTS AND LIMITATIONS: Storage LUTS, notably nocturia, and impaired sexual function are prominent in men being assessed for surgery. Sociodemographic and clinical evaluations were similar between arms. Overall mean IPSS and quality of life scores were 18.94 and 4.13, respectively. Trends were found across age groups, with older men suffering from higher rates of incontinence, nocturia, and erectile dysfunction, and younger men suffering from increased daytime frequency and voiding symptoms. Men undergoing UDS testing expressed high satisfaction with the procedure.
CONCLUSIONS: Men being considered for surgery have additional clinical features that may affect treatment decision making and outcomes, notably storage LUTS and impaired sexual function. PATIENT
SUMMARY: We describe initial assessment findings from a large clinical study of the treatment pathway for men suffering with bothersome urinary symptoms who were referred to hospital for further treatment, potentially including surgery. We report the patient characteristics and diagnostic test results, including symptom questionnaires, bladder diaries, flow rate tests, and urodynamics.
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Benign prostatic obstruction; Bladder outlet obstruction; Detrusor overactivity; Detrusor underactivity; Lower urinary tract symptoms; Patient-reported outcome measures; Prostate; Surgery; Underactive bladder; Urodynamics

Mesh:

Year:  2019        PMID: 31047905     DOI: 10.1016/j.euf.2019.04.006

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  6 in total

1.  Urodynamics tests for the diagnosis and management of bladder outlet obstruction in men: the UPSTREAM non-inferiority RCT.

Authors:  Amanda L Lewis; Grace J Young; Lucy E Selman; Caoimhe Rice; Clare Clement; Cynthia A Ochieng; Paul Abrams; Peter S Blair; Christopher Chapple; Cathryn Ma Glazener; Jeremy Horwood; John S McGrath; Sian Noble; Gordon T Taylor; J Athene Lane; Marcus J Drake
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

2.  Urodynamic findings in patients with nocturia and their associations with patient characteristics.

Authors:  Garson Chan; Liang G Qu; Johan Gani
Journal:  Can Urol Assoc J       Date:  2022-09       Impact factor: 2.052

Review 3.  Current Treatment for Benign Prostatic Hyperplasia.

Authors:  Arkadiusz Miernik; Christian Gratzke
Journal:  Dtsch Arztebl Int       Date:  2020-12-04       Impact factor: 5.594

4.  Personalized care for male LUTS: have we attained the holy grail?

Authors:  Sachin Malde; Eskinder Solomon
Journal:  Nat Rev Urol       Date:  2020-11       Impact factor: 14.432

5.  TReatIng Urinary symptoms in Men in Primary Healthcare using non-pharmacological and non-surgical interventions (TRIUMPH) compared with usual care: study protocol for a cluster randomised controlled trial.

Authors:  Jessica Frost; J Athene Lane; Nikki Cotterill; Mandy Fader; Lucy Hackshaw-McGeagh; Hashim Hashim; Margaret Macaulay; Stephanie J MacNeill; Sian Noble; Jonathan Rees; Matthew J Ridd; Luke Robles; Gordon Taylor; Jodi Taylor; Marcus J Drake; Jo Worthington
Journal:  Trials       Date:  2019-09-02       Impact factor: 2.279

6.  The relation between the storage symptoms before and after transurethral resection of the prostate, analysis of the risk factors and the prevention of the symptoms with solifenacin.

Authors:  Timucin Sipal; Hakan Akdere
Journal:  Int Braz J Urol       Date:  2020 Jul-Aug       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.